These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 36759199

  • 1. PSMA-GCK01: A Generator-Based 99mTc/188Re Theranostic Ligand for the Prostate-Specific Membrane Antigen.
    Cardinale J, Giesel FL, Wensky C, Rathke HG, Haberkorn U, Kratochwil C.
    J Nucl Med; 2023 Jul; 64(7):1069-1075. PubMed ID: 36759199
    [Abstract] [Full Text] [Related]

  • 2. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer.
    Mamlins E, Scharbert L, Cardinale J, Krotov M, Winter E, Rathke H, Strodel B, Ankrah AO, Sathekge M, Haberkorn U, Kratochwil C, Giesel FL.
    Mol Imaging Biol; 2024 Feb; 26(1):81-89. PubMed ID: 38066252
    [Abstract] [Full Text] [Related]

  • 3. Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of 99mTc and 188Re Theranostic Agents for Prostate Cancer.
    Pham TT, Hungnes IN, Rivas C, Cleaver J, Firth G, Blower PJ, Sosabowski J, Cook GJR, Livieratos L, Young JD, Pringle PG, Ma MT.
    J Nucl Med; 2024 Jul 01; 65(7):1087-1094. PubMed ID: 38844360
    [Abstract] [Full Text] [Related]

  • 4. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.
    Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.
    Nucl Med Biol; 2017 May 01; 48():36-44. PubMed ID: 28193503
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and Evaluation of 99mTc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography.
    Lu K, Zhang C, Zhang Z, Kuo HT, Colpo N, Bénard F, Lin KS.
    Molecules; 2023 Jun 29; 28(13):. PubMed ID: 37446782
    [Abstract] [Full Text] [Related]

  • 6. Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.
    García-Pérez FO, Davanzo J, López-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jímenez-Ríos MA, Scavuzzo A, Santana-Ríos Z, Medina-Ornelas S.
    Am J Nucl Med Mol Imaging; 2018 Jun 29; 8(5):332-340. PubMed ID: 30510850
    [Abstract] [Full Text] [Related]

  • 7. 99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients.
    Santos-Cuevas C, Davanzo J, Ferro-Flores G, García-Pérez FO, Ocampo-García B, Ignacio-Alvarez E, Gómez-Argumosa E, Pedraza-López M.
    Nucl Med Biol; 2017 Sep 29; 52():1-6. PubMed ID: 28575794
    [Abstract] [Full Text] [Related]

  • 8. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer.
    Santos-Cuevas C, Ferro-Flores G, García-Pérez FO, Jiménez-Mancilla N, Ramírez-Nava G, Ocampo-García B, Luna-Gutiérrez M, Azorín-Vega E, Davanzo J, Soldevilla-Gallardo I.
    Contrast Media Mol Imaging; 2018 Sep 29; 2018():5247153. PubMed ID: 30534027
    [Abstract] [Full Text] [Related]

  • 9. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
    J Nucl Med; 2017 Feb 29; 58(2):235-242. PubMed ID: 27635024
    [Abstract] [Full Text] [Related]

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Feb 29; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 11. Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer.
    Bolzati C, Gobbi C, Ferro-Flores G, Turato S, Ocampo-Garcia B, Carpanese D, Marzano C, Spolaore B, Fracasso G, Rosato A, Meléndez-Alafort L.
    Int J Mol Sci; 2023 Dec 29; 25(1):. PubMed ID: 38203663
    [Abstract] [Full Text] [Related]

  • 12. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.
    Xu X, Zhang J, Hu S, He S, Bao X, Ma G, Luo J, Cheng J, Zhang Y.
    Nucl Med Biol; 2017 May 29; 48():69-75. PubMed ID: 28273495
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug 29; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 14. Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer.
    Yang H, Gao Z, Xu X, Liu C, Hu S, Zhang J, Song S.
    Ann Nucl Med; 2023 Jan 29; 37(1):60-69. PubMed ID: 36346503
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, Notni J, Buckle T, van Oosterom MN, Steiger K, Ntziachristos V, Schwaiger M, van Leeuwen FWB, Wester HJ.
    J Nucl Med; 2019 Jan 29; 60(1):71-78. PubMed ID: 30237214
    [Abstract] [Full Text] [Related]

  • 16. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    J Nucl Med; 2013 Aug 29; 54(8):1369-76. PubMed ID: 23733925
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer.
    Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ.
    Sci Rep; 2020 Mar 06; 10(1):4179. PubMed ID: 32144340
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and Evaluation of 99mTc-Labeled DPro-Gly-Containing Tracers Targeting PSMA.
    Li Z, Jiang Y, Ruan Q, Yin G, Han P, Duan X, Zhang J.
    Mol Pharm; 2024 Oct 07; 21(10):5305-5314. PubMed ID: 39298677
    [Abstract] [Full Text] [Related]

  • 19. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for 64Cu/67Cu-Based Theranostics in Prostate Cancer.
    Kelly JM, Ponnala S, Amor-Coarasa A, Zia NA, Nikolopoulou A, Williams C, Schlyer DJ, DiMagno SG, Donnelly PS, Babich JW.
    Mol Pharm; 2020 Jun 01; 17(6):1954-1962. PubMed ID: 32286841
    [Abstract] [Full Text] [Related]

  • 20. Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer.
    Xiao D, Duan X, Gan Q, Zhang X, Zhang J.
    Molecules; 2020 Nov 26; 25(23):. PubMed ID: 33256058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.